One SR/MA [30] reported that XFZY was effective in treating LVEF (low-quality evidence), LVESD (low-quality evidence), NO (extremely low-quality evidence), ET-1 (extremely low-quality evidence), ICAM-1 (extremely low-quality evidence), SOD (extremely low-quality evidence), MDA (extremely low-quality evidence), BNP (extremely low-quality evidence), and CK-MB (extremely low-quality evidence) in patients with CHD. Here, EDN1 is linked to coronary artery disorder.